The Role of Dysfunctional CCK-1R in Cholelithogenesis

功能失调的 CCK-1R 在胆石形成中的作用

基本信息

  • 批准号:
    8018566
  • 负责人:
  • 金额:
    $ 31.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-01-15 至 2012-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The long-term objectives of this laboratory are to identify, localize, and estimate the lithogenic effects of pathophysiologically relevant gallstone (LITH) genes; understand at a fundamental level the genetic mechanisms of cholesterol gallstones; and explore the genotypes and phenotypes of LITH genes in mice and eventually in humans. Studies on both humans and mice have clearly demonstrated that a complex genetic basis determines the individual predisposition to develop cholesterol gallstones in response to environmental factors. A powerful genetic technique, quantitative trait locus (QTL) analysis can identify primary, usually rate- limiting genetic defects and discriminate them from secondary downstream pathophysiologic effects caused by mutations of the primary genes. We performed a QTL analysis in intercross progeny of gallstone-susceptible 129S3/SvlmJ mice and resistant AKR/J mice, and determined the subset of gallstone susceptibility genes possessed in the susceptible strain. Our molecular and genetic data from these mouse studies support the notion that dysfunctional cholecystokinin-1 receptor (CCK-1R) in the gallbladder plays a critical role in the formation of cholesterol gallstones in 129S3/SvlmJ mice challenged to a lithogenic diet. Furthermore, abnormalities in gallbladder emptying function in response to exogenously administered CCK-8 have been observed in patients with cholesterol gallstones, suggesting that altered structure and function of the gallbladder CCK-1R gene could be involved in the formation of cholesterol gallstones in humans. However, the identification of the lithogenic mechanisms of the mutated CCK-1R gene still remains a challenging task. This application will be focused on identifying the lithogenic effects of dysfunctional CCK-1R by systematically studying its pathophysiological functions in some "manufactured" mouse strains such as CCK-1R congenic mice and CCK-1R knockout mice. Also, we will investigate pathophysiological effects of gallbladder stasis on cholesterol crystallization and gallstone formation, as well as gene therapy of gallbladder dysmotility in these mice. In this application, the applicant proposes to (i) elucidate whether the mutated CCK-1R results in gallbladder stasis due to a defect in receptor-G protein coupling; (ii) determine the alterations induced by gallbladder hypomotility that account for rapid cholesterol crystallization and gallstone formation in mice with the mutated CCK-1R; and (iii) explore whether lentivirus-mediated transfer of the mouse CCK-1R gene prevents cholesterol gallstone formation in mice with gallbladder hypomotility. Due to the close homology between human and mouse genomes, the identification of lithogenic effects of dysfunctional CCK-1R in mice may elucidate previously unknown but pathophysiologically relevant genetic determinants of cholesterol cholelithiasis in humans.
描述(申请人提供):该实验室的长期目标是识别、定位和评估病理生理学相关的胆结石(LITH)基因的致石作用;在基础水平上了解胆固醇结石的遗传机制;并探索LITH基因在小鼠体内以及最终在人类中的基因类型和表型。对人类和老鼠的研究都清楚地表明,复杂的遗传基础决定了个体对环境因素产生胆固醇结石的易感性。作为一种强大的遗传技术,数量性状基因座(QTL)分析可以识别原发的、通常是限速的遗传缺陷,并将它们与由主基因突变引起的次要下游病理生理效应区分开来。我们对胆结石易感的129S3/SvlmJ小鼠和耐药的AKR/J小鼠的杂交后代进行了QTL分析,并确定了易感品系中存在的胆结石易感基因亚群。我们来自这些小鼠研究的分子和遗传学数据支持这样的观点,即胆囊中功能失调的CCK-1R在挑战致石饮食的129S3/SvlmJ小鼠的胆固醇结石形成中起关键作用。此外,在胆固醇结石患者中观察到外源性给予CCK-8导致的胆囊排空功能异常,这表明胆囊CCK-1R基因的结构和功能改变可能参与了人类胆固醇结石的形成。然而,对突变的CCK-1R基因的致石机制的鉴定仍然是一个具有挑战性的任务。这项应用将集中于通过系统地研究CCK-1R在一些“制造”的小鼠品系中的病理生理功能来鉴定功能失调的CCK-1R的致石作用,例如CCK-1R同源基因小鼠和CCK-1R基因敲除小鼠。此外,我们还将研究胆汁淤积对胆固醇结晶和胆结石形成的病理生理影响,以及对这些小鼠胆汁动力障碍的基因治疗。在本申请中,申请人提议:(I)阐明突变的CCK-1R是否由于受体-G蛋白偶联缺陷而导致胆囊停滞;(Ii)确定携带CCK-1R突变的小鼠的胆固醇快速结晶和胆结石形成的原因是由胆囊动力低下引起的变化;以及(Iii)探索慢病毒介导的小鼠CCK-1R基因转移是否能防止胆囊运动低下的小鼠胆固醇结石的形成。由于人类和小鼠基因组之间的高度同源性,鉴定功能失调的CCK-1R在小鼠中的致石作用可能阐明先前未知的、但与人类胆固醇胆石症的病理生理相关的遗传决定因素。

项目成果

期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol.
  • DOI:
    10.1111/eci.12058
  • 发表时间:
    2013-04
  • 期刊:
  • 影响因子:
    5.5
  • 作者:
    Wang HH;Portincasa P;de Bari O;Liu KJ;Garruti G;Neuschwander-Tetri BA;Wang DQ
  • 通讯作者:
    Wang DQ
The deletion of the estrogen receptor α gene reduces susceptibility to estrogen-induced cholesterol cholelithiasis in female mice.
  • DOI:
    10.1016/j.bbadis.2015.07.020
  • 发表时间:
    2015-10
  • 期刊:
  • 影响因子:
    0
  • 作者:
    de Bari O;Wang HH;Portincasa P;Liu M;Wang DQ
  • 通讯作者:
    Wang DQ
New insights into the molecular mechanism of intestinal fatty acid absorption.
The cholecystokinin-1 receptor antagonist devazepide increases cholesterol cholelithogenesis in mice.
胆囊收缩素-1 受体拮抗剂 devazepide 可增加小鼠体内胆固醇胆石生成。
A novel therapeutic effect of statins on nephrogenic diabetes insipidus.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID Q WANG其他文献

DAVID Q WANG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID Q WANG', 18)}}的其他基金

GPR30 and hepatic cholesterol metabolism
GPR30 与肝脏胆固醇代谢
  • 批准号:
    10213710
  • 财政年份:
    2020
  • 资助金额:
    $ 31.24万
  • 项目类别:
Apolipoprotein A5 and Gallstone Formation
载脂蛋白 A5 和胆结石形成
  • 批准号:
    9914001
  • 财政年份:
    2018
  • 资助金额:
    $ 31.24万
  • 项目类别:
Gene therapy of alcoholic liver disease
酒精性肝病的基因治疗
  • 批准号:
    9547735
  • 财政年份:
    2017
  • 资助金额:
    $ 31.24万
  • 项目类别:
Gene therapy of alcoholic liver disease
酒精性肝病的基因治疗
  • 批准号:
    9297754
  • 财政年份:
    2017
  • 资助金额:
    $ 31.24万
  • 项目类别:
GPR30 and Hepatic Cholesterol Homeostasis
GPR30 和肝脏胆固醇稳态
  • 批准号:
    8943150
  • 财政年份:
    2015
  • 资助金额:
    $ 31.24万
  • 项目类别:
GPR30 and Hepatic Cholesterol Homeostasis
GPR30 和肝脏胆固醇稳态
  • 批准号:
    9302754
  • 财政年份:
    2015
  • 资助金额:
    $ 31.24万
  • 项目类别:
GPR30 and Hepatic Cholesterol Homeostasis
GPR30 和肝脏胆固醇稳态
  • 批准号:
    9857099
  • 财政年份:
    2015
  • 资助金额:
    $ 31.24万
  • 项目类别:
Role of GPR30 in Hepatic Lipid Metabolism
GPR30 在肝脏脂质代谢中的作用
  • 批准号:
    8917341
  • 财政年份:
    2014
  • 资助金额:
    $ 31.24万
  • 项目类别:
The Role of Dysfunctional CCK-1R in Cholelithogenesis
功能失调的 CCK-1R 在胆石形成中的作用
  • 批准号:
    7369647
  • 财政年份:
    2008
  • 资助金额:
    $ 31.24万
  • 项目类别:
The Role of Dysfunctional CCK-1R in Cholelithogenesis
功能失调的 CCK-1R 在胆石形成中的作用
  • 批准号:
    7556320
  • 财政年份:
    2008
  • 资助金额:
    $ 31.24万
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Standard Grant
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 31.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了